Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 3973-3979

  Drusano, G L ^a   Okusanya, Olanrewaju O ^a   Okusanya, Adedoyin ^a   Van Scoy, Brian ^a   Brown, D L ^a   Kulawy, Robert ^a   Sörgel, Fritz ^b   Heine, Henry S ^c   Louie, Arnold ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b Institute for Biomedical and Pharmaceutical Research   (Germany)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACILLUS ANTHRACIS; COLONY FORMING UNIT; HEAT SHOCK; HOLLOW FIBER; MATHEMATICAL MODEL; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; VARIANCE;

ANTHRAX; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HEAT-SHOCK RESPONSE; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; MUTATION; SPORES, BACTERIAL; TIME FACTORS;

EID: 55849106998     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00453-08     Document Type: Article

References (13)

1. Blank, S., L. C. Moskin, and J. R. Zucker. 2003. An ounce of prevention is a ton of work: mass antibiotic prophylaxis for anthrax, New York City, 2001. Emerg. Infect. Dis. 9:615-622.
2. Brookmeyer, R., E. Johnson, and R. Bollinger. 2003. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc. Natl. Acad. Sci. USA 100:10129-10132.
3. Clinical and Laboratory Standards Institute. 2006. Document M7-A7. Methods for dilutional antimicrobial susceptibility testing for bacteria that grow aerobically; approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
4. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
5. Deziel, M., H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Bassett, L. Miller, K. Bush, M. Kelly, and G. L. Drusano. 2005. Identification of effective antimicrobial regimens for use in humans for the therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106.
6. Heine, H. S., J. Bassett, L. Miller, J. M. Hartings, B. E. Ivins, M. L. Pitt, D. Fritz, S. L. Norris, and W. R. Byrne. 2007. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob. Agents Chemother. 51:1373-1379.
7. Inglesby, T., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauser, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, K. Tonat, and the Working Group on Civilian Biodefense. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
8. Jefferds, M. D., K. Laserson, A. M. Fry, S. Roy, J. Hayslett, L. Grummer-Stawn, L. Kettel-Kahn, A. Schuchat, and Selected Members of the Centers for Disease Control and Prevention Anthrax Adherence Team. 2002. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg. Infect. Dis. 8:1138-1144.
9. Karabalut, N., and G. L. Drusano. 1993. Pharmacokinetics of the quinolone antimicrobial agents, p. 195-223. In D. C. Hooper and J. S. Wolfson (ed.), Quinolone antimicrobial agents, 2nd ed. American Society for Microbiology, Washington, DC.
10. Leary, R., R. Jelliffe, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. In Proc. 14th IEEE Symp. Comput.-Based Med. Syst. IEEE Computer Society, Bethesda, MD.
11. National Committee for Clinical Laboratory Standards. 1999. Document M26-A. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines. National Committee for Clinical Laboratory Standards, Wayne, PA.
12. Partridge, R., J. Alexander, T. Lawrence, and S. Suner. 2003. Medical counterbioterrorism: the response to provide anthrax prophylaxis to New York City US Postal Service employees. Ann. Emerg. Med. 41:441-446.
13. Russell, P. K. 2007. Project Bioshield: what it is, why it is needed and its accomplishments so far. Clin. Infect. Dis. 45(Suppl. 1):S68-S72.